US panel gives nod to GSK/Genmab's Arzerra for leukaemia

GlaxoSmithKline/Genmab's anti-CD20 monoclonal antibody Arzerra (ofatumumab) is reasonably likely to have a clinical benefit in heavily pretreated patients with chronic lymphocytic leukaemia (CLL), the US FDA's outside advisors say.

GlaxoSmithKline/Genmab's anti-CD20 monoclonal antibody Arzerra (ofatumumab) is reasonably likely to have a clinical benefit in heavily pretreated patients with chronic lymphocytic leukaemia (CLL), the US FDA's outside advisors say.

In a 10 to three vote, the oncologic drugs advisory committee (ODAC) said objective response rates in a single-arm trial...

More from Anticancer

More from Therapeutic Category

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.